Development Corp., is helping raise money for a women-focused cancer research initiative. The campaign, which will run through June, is in its second year.
Health care systems scramble to offer latest in cancer care
Indiana University Health’s new Schwarz Cancer Center is the latest addition to a crowded landscape of cancer centers and hospital oncology programs popping up around central Indiana.Read More
Researchers on Wednesday reported the largest-ever one-year decline in the U.S. cancer death rate, a drop they credited to advances in lung-tumor treatments.
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
The treatment costs $375,000 or $475,000, depending on whether it is used for advanced lymphoma or pediatric leukemia. Hospital stays can add hundreds of thousands of dollars to the cost of care.
The cancer center, opened in 2008, is now one of just 51 “comprehensive cancer centers” in the nation and the only one in Indiana.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.
Bristol-Myers Squibb Co. on Friday won a shareholder vote to approve its takeover of Celgene Corp., paving the way to close the largest pharmaceutical merger in history and create a cancer-drug giant.
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.
The researchers are testing the effectiveness of a small, targeted molecule to prevent or reverse chemotherapy-induced peripheral neuropathy—a nerve problem that causes pain, numbness and tingling.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The center aims to develop new treatments for diabetes, severe wounds, and damage to tissues and organs caused by age, disease or trauma.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
The ads for the metastatic breast cancer drug Verzenio show women in their 50s and 60s looking resolute and indomitable, surrounded by smiling friends and family.